Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease

Paula T. Trzepacz, Jeffrey Cummings, Thomas Konechnik, Tammy D. Forrester, Curtis Chang, Ellen B. Dennehy, Brian A. Willis, Catherine Shuler, Linda B. Tabas, Constantine Lyketsos

Research output: Contribution to journalArticle

Abstract

Background: Mibampator, an amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor potentiator, was evaluated for treatment of agitation and aggression (A/A) in Alzheimer's disease (AD). Methods: Outpatients (n = 132) with probable AD and A/A randomized to 12 weeks of double-blind treatment with 3-mg po mibampator or placebo were assessed using the 4-domain A/A subscale of the Neuropsychiatric Inventory (NPI-4-A/A) derived from the Neuropsychiatric Inventory. Secondary measures included the Cohen-Mansfield Agitation Inventory, Cornell Scale for Depression in Dementia, Frontal Systems Behavior Inventory (FrSBe), and Alzheimer's Disease Assessment Scale-Cognitive. Efficacy was analyzed using mixed-effects model repeated measures from baseline to endpoint. Adverse events (AEs), labs, vital signs, and electrocardiograms were monitored. Results: Baseline characteristics were comparable between groups. Both groups improved on the NPI-4-A/A, but without group differences. Among secondaries, mibampator was significantly better (p = 0.007) than placebo only on the FrSBe. AEs were similar between groups. One death occurred in the placebo group. Conclusion: Possible explanations for no significant group differences include caregiver, drug target engagement, and design issues.

Original languageEnglish (US)
Pages (from-to)707-719
Number of pages13
JournalInternational psychogeriatrics
Volume25
Issue number5
DOIs
StatePublished - May 2013

Keywords

  • AMPA
  • Alzheimer's disease
  • Neuropsychiatric Inventory
  • aggression
  • agitation
  • glutamate
  • mibampator
  • neuropsychiatric symptoms

ASJC Scopus subject areas

  • Clinical Psychology
  • Gerontology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease'. Together they form a unique fingerprint.

  • Cite this

    Trzepacz, P. T., Cummings, J., Konechnik, T., Forrester, T. D., Chang, C., Dennehy, E. B., Willis, B. A., Shuler, C., Tabas, L. B., & Lyketsos, C. (2013). Mibampator (LY451395) randomized clinical trial for agitation/aggression in Alzheimer's disease. International psychogeriatrics, 25(5), 707-719. https://doi.org/10.1017/S1041610212002141